{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:52:12Z","timestamp":1777564332801,"version":"3.51.4"},"reference-count":60,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.revmed.2020.02.014","type":"journal-article","created":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T09:28:42Z","timestamp":1584610122000},"page":"396-403","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["La maladie goutteuse"],"prefix":"10.1016","volume":"41","author":[{"given":"A.","family":"Scuiller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Pascart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Oehler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.revmed.2020.02.014_bib0305","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1136\/annrheumdis-2013-204463","article-title":"Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study","volume":"74","author":"Kuo","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.revmed.2020.02.014_bib0310","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/art.30520","article-title":"Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008","volume":"63","author":"Zhu","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.revmed.2020.02.014_bib0315","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/acr.22660","article-title":"Prevalence of Gout in the adult population of France","volume":"68","author":"Bardin","year":"2016","journal-title":"Arthritis Care Res"},{"issue":"5","key":"10.1016\/j.revmed.2020.02.014_bib0320","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1136\/annrheumdis-2011-201254","article-title":"Epidemiology of gout and hyperuricaemia in Italy during the years 2005-2009: a nationwide population-based study","volume":"72","author":"Trifir\u00f2","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.revmed.2020.02.014_bib0325","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1093\/rheumatology\/ker361","article-title":"National prevalence of gout derived from administrative health data in Aotearoa New Zealand","volume":"51","author":"Winnard","year":"2012","journal-title":"Rheumatol"},{"issue":"1","key":"10.1016\/j.revmed.2020.02.014_bib0330","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1136\/ard.56.1.22","article-title":"Gout is on the increase in New Zealand","volume":"56","author":"Klemp","year":"1997","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.revmed.2020.02.014_bib0335","first-page":"464","article-title":"GOSPEL: prospective survey of gout in France","volume":"79","author":"Liot\u00e9","year":"2012","journal-title":"Part I: design and patient characteristics (n=1003). Joint Bone Spine"},{"issue":"1","key":"10.1016\/j.revmed.2020.02.014_bib0340","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00360-008-0291-7","article-title":"Lessons from comparative physiology: could uric acid represent a physiologic alarm signal gone awry in western society?","volume":"179","author":"Johnson","year":"2009","journal-title":"J Comp Physiol B"},{"issue":"S3","key":"10.1016\/j.revmed.2020.02.014_bib0345","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S1169-8330(11)70021-7","article-title":"De l\u2019hyperuric\u00e9mie \u00e0 la goutte\u00a0: physiopathologie","volume":"78","author":"Korng Ea","year":"2011","journal-title":"Rev Rhum"},{"issue":"2","key":"10.1016\/j.revmed.2020.02.014_bib0350","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/art.1780150209","article-title":"The influence of temperature on the solubility of monosodium urate","volume":"15","author":"Loeb","year":"1972","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.revmed.2020.02.014_bib0355","doi-asserted-by":"crossref","first-page":"13184","DOI":"10.1038\/s41598-018-31282-z","article-title":"Genetics of serum urate concentrations and gout in a high-risk population, patients with chronic kidney disease","volume":"8","author":"Jing","year":"2018","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.revmed.2020.02.014_bib0360","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.rdc.2017.04.004","article-title":"Genomic influences on Hyperuricemia and Gout","volume":"43","author":"Merriman","year":"2017","journal-title":"Rheum Dis Clin North Am"},{"issue":"2","key":"10.1016\/j.revmed.2020.02.014_bib0365","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/art.38203","article-title":"Use of diuretics and risk of incident gout: a population-based case-control study","volume":"66","author":"Bruderer","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.revmed.2020.02.014_bib0370","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1136\/annrheumdis-2012-202589","article-title":"Low-dose aspirin use and recurrent gout attacks","volume":"73","author":"Zhang","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.revmed.2020.02.014_bib0375","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/RHU.0000000000000297","article-title":"Effect of antituberculous drugs on serum uric acid and urine uric acid excretion","volume":"21","author":"Louthrenoo","year":"2015","journal-title":"J Clin Rheumatol"},{"issue":"9711","key":"10.1016\/j.revmed.2020.02.014_bib0380","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0140-6736(09)60883-7","volume":"375","author":"Richette","year":"2010","journal-title":"Gout. Lancet"},{"key":"10.1016\/j.revmed.2020.02.014_bib0385","doi-asserted-by":"crossref","first-page":"j1794","DOI":"10.1136\/bmj.j1794","article-title":"The dietary approaches to stop hypertension (DASH) diet, Western diet, and risk of gout in men: prospective cohort study","volume":"357","author":"Rai","year":"2017","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.revmed.2020.02.014_bib0390","doi-asserted-by":"crossref","first-page":"E981","DOI":"10.3390\/nu10080981","article-title":"Sugar-sweetened soft drinks and fructose consumption are associated with hyperuricemia: cross-sectional analysis from the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil)","volume":"10","author":"Siqueira","year":"2018","journal-title":"Nutrients"},{"issue":"2","key":"10.1016\/j.revmed.2020.02.014_bib0395","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.rdc.2014.01.001","article-title":"Epidemiology of gout","volume":"40","author":"Roddy","year":"2014","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.revmed.2020.02.014_bib0400","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.rhum.2006.09.011","article-title":"Formes cliniques rares de la goutte","volume":"74","author":"Chal\u00e8s","year":"2007","journal-title":"Rev Rhum"},{"issue":"8","key":"10.1016\/j.revmed.2020.02.014_bib0405","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1007\/s10067-016-3309-7","article-title":"Tendon involvement in patients with gout: an ultrasound study of prevalence","volume":"35","author":"Ventura-R\u00edos","year":"2016","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.revmed.2020.02.014_bib0410","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.rhum.2013.04.007","article-title":"Goutte rachidienne\u00a0: cinq cas, dont deux r\u00e9v\u00e9lateurs de la goutte","volume":"81","author":"Wendling","year":"2014","journal-title":"Rev Rhum"},{"issue":"1","key":"10.1016\/j.revmed.2020.02.014_bib0415","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1053\/j.ajkd.2016.11.006","article-title":"AJKD atlas of renal pathology: gouty nephropathy","volume":"69","author":"Lusco","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.revmed.2020.02.014_bib0420","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1136\/annrheumdis-2014-206364","article-title":"Performance of classification criteria for gout in early and established disease","volume":"75","author":"Taylor","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.revmed.2020.02.014_bib0425","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1136\/annrheumdis-2015-208237","article-title":"2015\u00a0Gout classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"74","author":"Neogi","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.revmed.2020.02.014_bib0430","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/ard.56.11.696a","article-title":"Serum uric acid in acute gout","volume":"56","author":"Logan","year":"1997","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.revmed.2020.02.014_bib0435","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.crad.2011.04.011","article-title":"A re-look at an old disease: a multimodality review on gout","volume":"66","author":"Dhanda","year":"2011","journal-title":"Clin Radiol"},{"issue":"6","key":"10.1016\/j.revmed.2020.02.014_bib0440","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.ultrasmedbio.2016.01.014","article-title":"Sonographic findings in gouty arthritis: diagnostic value and association with disease duration","volume":"42","author":"Elsaman","year":"2016","journal-title":"Ultrasound Med Biol"},{"issue":"1","key":"10.1016\/j.revmed.2020.02.014_bib0445","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jbspin.2014.03.011","article-title":"Ultrasound in gout: a useful tool for following urate-lowering therapy","volume":"82","author":"Ottaviani","year":"2015","journal-title":"Joint Bone Spine"},{"issue":"12","key":"10.1016\/j.revmed.2020.02.014_bib0450","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s11926-018-0783-8","article-title":"Gout:Update on dual-energy computed tomography with emphasis on artifact identification","volume":"20","author":"Garner","year":"2018","journal-title":"Curr Rheumatol Rep"},{"issue":"5","key":"10.1016\/j.revmed.2020.02.014_bib0455","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1136\/annrheumdis-2014-206397","article-title":"Urate crystal deposition in asymptomatic hyperuricaemia and symptomatic gout: a dual energy CT study","volume":"74","author":"Dalbeth","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.revmed.2020.02.014_bib0460","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.semarthrit.2018.04.006","article-title":"Gout of the axial joint-A patient level systemic review","volume":"48","author":"Zhang","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.revmed.2020.02.014_bib0465","first-page":"331","article-title":"Local ice therapy during bouts of acute gouty arthritis","volume":"29","author":"Schlesinger","year":"2002","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.revmed.2020.02.014_bib0470","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.27327","article-title":"High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study","volume":"62","author":"Terkeltaub","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.revmed.2020.02.014_bib0475","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016\u00a0updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.revmed.2020.02.014_bib0480","doi-asserted-by":"crossref","first-page":"684","DOI":"10.2174\/1381612824999180115103951","article-title":"Colchicine in Gout: an update","volume":"24","author":"Pascart","year":"2018","journal-title":"Curr Pharm Des"},{"issue":"7","key":"10.1016\/j.revmed.2020.02.014_bib0485","doi-asserted-by":"crossref","first-page":"464","DOI":"10.7326\/M14-2070","article-title":"Oral prednisolone in the treatment of acute gout: a pragmatic, multicenter, double-blind, randomized trial","volume":"164","author":"Rainer","year":"2016","journal-title":"Ann Intern Med"},{"issue":"9627","key":"10.1016\/j.revmed.2020.02.014_bib0490","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1016\/S0140-6736(08)60799-0","article-title":"Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial","volume":"371","author":"Janssens","year":"2008","journal-title":"Lancet Lond Engl"},{"issue":"2","key":"10.1016\/j.revmed.2020.02.014_bib0495","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.amjmed.2010.09.012","article-title":"Prevalence of contraindications and prescription of pharmacologic therapies for gout","volume":"124","author":"Keenan","year":"2011","journal-title":"Am J Med"},{"issue":"8","key":"10.1016\/j.revmed.2020.02.014_bib0500","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1002\/art.30389","article-title":"Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4\/P-glycoprotein inhibitors","volume":"63","author":"Terkeltaub","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"7\u20138","key":"10.1016\/j.revmed.2020.02.014_bib0505","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1345\/aph.1H064","article-title":"Rhabdomyolysis in a patient treated with colchicine and atorvastatin","volume":"40","author":"Tufan","year":"2006","journal-title":"Ann Pharmacother"},{"issue":"6","key":"10.1016\/j.revmed.2020.02.014_bib0510","first-page":"687","article-title":"GOSPEL 2\u00a0-\u00a0Colchicine for the treatment of gout flares in France\u00a0\u2014\u00a0a GOSPEL survey subgroup analysis","volume":"83","author":"Pascart","year":"2016","journal-title":"Doses used in common practices regardless of renal impairment and age. Joint Bone Spine"},{"key":"10.1016\/j.revmed.2020.02.014_bib0515","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1093\/rheumatology\/kez203","article-title":"Difficult-to-treat gout flares: eligibility for interleukin-1\u00a0inhibition in private practice is uncommon according to current EMA approval","volume":"58","author":"Pascart","year":"2019","journal-title":"Rheumatol"},{"issue":"10","key":"10.1016\/j.revmed.2020.02.014_bib0520","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1002\/art.27600","article-title":"Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study","volume":"62","author":"So","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.revmed.2020.02.014_bib0525","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/art.23007","article-title":"Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout?","volume":"57","author":"Perez-Ruiz","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.revmed.2020.02.014_bib0530","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jbspin.2017.04.002","article-title":"GOSPEL 3: management of gout by primary-care physicians and office-based rheumatologists in France in the early 21st century\u00a0\u2014\u00a0comparison with 2006\u00a0EULAR Recommendations","volume":"84","author":"Goossens","year":"2017","journal-title":"Joint Bone Spine"},{"issue":"3","key":"10.1016\/j.revmed.2020.02.014_bib0535","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jbspin.2017.03.013","article-title":"Persistent clinical inertia in gout in 2014: an observational French longitudinal patient database study","volume":"85","author":"Maravic","year":"2018","journal-title":"Joint Bone Spine"},{"issue":"6","key":"10.1016\/j.revmed.2020.02.014_bib0540","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1136\/annrheumdis-2012-201676","article-title":"Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study","volume":"72","author":"Rees","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.revmed.2020.02.014_bib0545","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.semarthrit.2016.03.014","article-title":"Racial disparities in the risk of Stevens\u2013Johnson Syndrome and toxic epidermal necrolysis as urate-lowering drug adverse events in the United States","volume":"46","author":"Lu","year":"2016","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.revmed.2020.02.014_bib0550","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1002\/art.34488","article-title":"Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol","volume":"64","author":"Stamp","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.revmed.2020.02.014_bib0555","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","article-title":"The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial","volume":"12","author":"Becker","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"13","key":"10.1016\/j.revmed.2020.02.014_bib0560","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout","volume":"378","author":"White","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2020.02.014_bib0565","article-title":"Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4-5\u00a0chronic kidney disease not yet on dialysis","author":"Kim","year":"2019","journal-title":"Korean J Intern Med"},{"issue":"4","key":"10.1016\/j.revmed.2020.02.014_bib0570","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jbspin.2014.02.015","article-title":"Rational pharmacotherapy (RPT) in goutology: Define the serum uric acid target & treat-to-target patient cohort and review on urate lowering therapy (ULT) applying synthetic drugs","volume":"82","author":"Jansen","year":"2015","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.revmed.2020.02.014_bib0575","first-page":"CD010457","article-title":"Uricosuric medications for chronic gout","volume":"11","author":"Kydd","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.revmed.2020.02.014_bib0580","article-title":"Lesinurad, a selective URAT-1\u00a0inhibitor with a novel mechanism in combination with a xanthine oxidase inhibitor, for hyperuricemia associated with gout","author":"Huneycutt","year":"2017","journal-title":"J Pharm Pract"},{"issue":"7","key":"10.1016\/j.revmed.2020.02.014_bib0585","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.1169","article-title":"Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials","volume":"306","author":"Sundy","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.revmed.2020.02.014_bib0590","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2147\/OARRR.S176951","article-title":"Impact of pegloticase on patient outcomes in refractory gout: current perspectives","volume":"10","author":"Cunha","year":"2018","journal-title":"Open Access Rheumatol"},{"issue":"10","key":"10.1016\/j.revmed.2020.02.014_bib0595","first-page":"2093","article-title":"Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study","volume":"34","author":"Richette","year":"2007","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.revmed.2020.02.014_bib0300","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1136\/ard.62.6.497","volume":"62","author":"Bardin","year":"2003","journal-title":"Ann Rheum Dis"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866320300801?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866320300801?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:42:37Z","timestamp":1759336957000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866320300801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0248866320300801"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2020.02.014","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"La maladie goutteuse","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2020.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}